Neoleukin Therapeutics, Inc. (NLTX): Price and Financial Metrics

Neoleukin Therapeutics, Inc. (NLTX): $1.00

-0.02 (-1.97%)

POWR Rating

Component Grades













Add NLTX to Watchlist
Sign Up

Industry: Biotech



in industry

NLTX Stock Price Chart Interactive Chart >

Price chart for NLTX

NLTX Price/Volume Stats

Current price $1.00 52-week high $11.10
Prev. close $1.02 52-week low $0.92
Day low $0.96 Volume 196,800
Day high $1.03 Avg. volume 263,320
50-day MA $1.44 Dividend yield N/A
200-day MA $4.37 Market Cap 42.50M

Neoleukin Therapeutics, Inc. (NLTX) Company Bio

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops medicines to treat serious diseases, including cancer, inflammatory, and autoimmune disorders.

NLTX Latest News Stream

Event/Time News Detail
Loading, please wait...

NLTX Latest Social Stream

Loading social stream, please wait...

View Full NLTX Social Stream

Latest NLTX News From Around the Web

Below are the latest news stories about Neoleukin Therapeutics Inc that investors may wish to consider to help them evaluate NLTX as an investment opportunity.

Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022

SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced , today announced it will report full year 2021 financial results on Tuesday, March 1, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as f

Yahoo | February 22, 2022

Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cytokinetics (CYTK) and Neoleukin Therapeutics (NLTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report), Cytokinetics (CYTK – Research Report) and Neoleukin Therapeutics (NLTX – Research Report). Boston Scientific (BSX) In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific. The company's shares closed last Tuesday at $43.84. According to TipRanks.

Christine Brown on TipRanks | February 15, 2022

Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference

SEATTLE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Oncology Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 1:30 p.m. Eastern. The webcast presentation can be accessed from the investo

Yahoo | February 3, 2022

As Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) drops to US$138m market cap, insiders might rethink their US$1.4m stock purchase earlier this year

The recent 15% drop in Neoleukin Therapeutics, Inc.'s ( NASDAQ:NLTX ) stock could come as a blow to insiders who...

Yahoo | January 24, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neoleukin Therapeutics (NLTX – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments. Neoleukin Therapeutics (NLTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Neoleukin Therapeutics, with a price target of $22.00. The company's shares closed last Monday at $4.20. According to TipRanks.

Howard Kim on TipRanks | January 11, 2022

Read More 'NLTX' Stories Here

NLTX Price Returns

1-mo -20.00%
3-mo -62.96%
6-mo -80.43%
1-year -90.00%
3-year -61.83%
5-year -92.70%
YTD -79.25%
2021 -65.82%
2020 14.45%
2019 470.37%
2018 -81.63%
2017 -28.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9324 seconds.